Key facts
- It has raised $120.0M; the latest was Debt - General ($22.2M) in Oct 2024.
- Notable investors include SoftBank Investment Advisers, European Union, Irving Investors, Gilde Healthcare, Tao Capital Partners — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for LUMICKS
- ·The full record, as it builds
Funding rounds
No funding rounds for LUMICKS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LUMICKS
Developer of dynamic single-molecule and cell avidity analysis instruments designed to reveal unique molecular and cellular interactions. The company's technology permits the disruptive techniques of live measurement and imaging of interactions at the single-molecule level, which is key for preventing and curing cancer and other diseases, enabling researchers to get insight into the fundamental cause of disease and potential for drug optimization.
- Sector
- Healthcare
- HQ
- Amsterdam, Netherlands
- Founded
- 2014
- Employees
- 170
- Website
- lumicks.com/
- Ownership
- Privately Held (backing)
LUMICKS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LUMICKS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LUMICKS in its N-PORT filings yet. We sweep new filings monthly.